Aspire Biopharma Holdings (ASBP) EBT Margin (2025 - 2026)

Aspire Biopharma Holdings' (ASBP) quarterly EBT Margin came in at 2009.61% in Q2 2026, up 82.32% quarter-over-quarter from 11367.02% in Q1 2026.

Analysis

Aspire Biopharma Holdings (ASBP) EBT Margin (2025 - 2026) Analysis & Trends

Aspire Biopharma Holdings (ASBP) has reported EBT Margin for 2 consecutive years, with 2009.61% the latest figure, recorded in Q2 2026.

On a quarterly basis, EBT Margin changed N/A year-over-year to 2009.61% in Q2 2026; TTM through Jun 2026 was 15563.75%, a N/A change from a year earlier, with the FY2025 full-year figure at 394725.06%, changed N/A from the prior year.
EBT Margin was 2009.61% for Q2 2026 at Aspire Biopharma Holdings, up from 11367.02% in the prior quarter.
Over five years, EBT Margin peaked at 2009.61% in Q2 2026 and troughed at 189692.96% in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Amgen	208.48 Bn	194.49 Bn	7.24 Bn	27.53%
2	Gilead Sciences	186.29 Bn	183.02 Bn	6.22 Bn	-131.41%
3	Vertex Pharmaceuticals	128.79 Bn	120.93 Bn	2.84 Bn	41.75%
4	Regeneron Pharmaceuticals	80.66 Bn	72.67 Bn	3.93 Bn	35.61%
5	Moderna	61.46 Bn	56.32 Bn	52.00 Mn	-528.97%
6	Argenx Se	61.28 Bn	56.10 Bn	1.37 Bn	35.78%
7	Alnylam Pharmaceuticals	32.04 Bn	28.73 Bn	992.69 Mn	13.77%
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn	4.84%
9	Roivant Sciences	28.74 Bn	29.43 Bn	1.16 Mn	-20,427.46%
10	Aspire Biopharma Holdings	64.13 Mn	51.96 Mn	-30,086.00	-2,009.61%

Historic Data

Download Data